ID: h-ab1c104108
Hypothesis
Convergent NF-κB enhancers across diverse priming stimuli share therapeutic vulnerability to BET inhibitors
Despite different initial triggers (LPS, β-amyloid, aging), primed microglia may converge on a common 'epigenetic priming signature' characterized by BRD4-occupied poised enhancers at NF-κB target genes (including TNF, IL1B, CCL2, and TR.
immunology
EvidencePending (0%)📖 5 cit🗣 1 debates✓ 5 support✗ 2 oppose
✓ All Quality Gates Passed
🧪 Overview
Despite different initial triggers (LPS, β-amyloid, aging), primed microglia may converge on a common 'epigenetic priming signature' characterized by BRD4-occupied poised enhancers at NF-κB target genes (including TNF, IL1B, CCL2, and TREM2). This convergent chromatin remodeling would explain why BET inhibitors produce similar therapeutic effects regardless of priming stimulus, as they disrupt a shared downstream transcriptional amplifier rather than stimulus-specific upstream pathways. The testable prediction is that BRD4 ChIP-seq in microglia primed by distinct stimuli will reveal overlapping enhancer landscapes, and that CRISPR-mediated deletion of a representative converged enhancer will abrogate hyperinflammatory responses across all priming conditions.
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["BRD4 BET Bromodomain<br/>Transcription Amplification"]
B["NF-kB Enhancer<br/>Activity Amplification"]
C["Convergent NF-kB<br/>Enhancers Across Stimuli"]
D["Pro-Inflammatory Gene<br/>Expression Sustained"]
E["BET Inhibitor<br/>Therapeutic Vulnerability"]
F["BRD4 as<br/>Enhancer Amplification Target"]
A --> B
B --> C
C --> D
D --> E
E --> F
style A fill:#7b1fa2,stroke:#ce93d8,color:#ce93d8
style F fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7⚖️ Evidence
⚖️ Evidence Matrix5 supports2 contradicts
Supports
Estradiol Prevents Amyloid Beta-Induced Mitochondrial Dysfunction and Neurotoxicity in Alzheimer's Disease via AMPK-Dependent Suppression of NF-κB Signaling.
Supports
The Pivotal Role of NF-kB in the Pathogenesis and Therapeutics of Alzheimer's Disease.
Supports
Artemisinin Attenuates Amyloid-Induced Brain Inflammation and Memory Impairments by Modulating TLR4/NF-κB Signaling.
Supports
Betaine Mitigates Amyloid-β-Associated Neuroinflammation by Suppressing the NLRP3 and NF-κB Signaling Pathways in Microglial Cells.
Supports
PINK1-dependent NFKB signaling contributes to amyloid pathology in Alzheimer disease.
Contradicts
BET inhibition broadly reduces neuroinflammation but acts through stimulus-specific enhancer sets, not a convergent shared NF-κB enhancer program; microglial enhancer landscapes after LPS versus amyloid-β priming show partially non-overlapping BRD4 occupancy patterns
PMID:40305227moderate
Contradicts
Most BET inhibitors (JQ1, OTX015) have poor blood-brain barrier penetration; brain-permeable BET inhibitors are still in early development, making clinical CNS microglial targeting challenging and suggesting in vivo selectivity of the proposed therapy is unproven
PMID:38142510moderate
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — BRD4
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for BRD4 from GTEx v10.
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for BRD4.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▲ 0.0%
Volatility
High
0.0897
Events (7d)
1
Price History
▲11.8%💾 Resource Usage
LLM Tokens
14,248
$0.0855
Total Cost
$0.0855
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF CRISPR-Cas9 editing deletes a representative convergent BRD4-occupied enhancer (chr11:60.5-60.7 Mb upstream of TREM2) in iPSC-derived microglia-like cells, THEN treatment with JQ1 (300 nM BET inhib | CRISPR-deleted cells show blunted inflammatory response (TNF release <50 pg/mL) across all challenge conditions compared to wild-type cells, with BET inhibitor | — no observation — | pending | 0.68 |
| IF primary murine microglia are primed with three mechanistically distinct stimuli (LPS 100 ng/mL, aggregated Aβ42 2 μM, and serum derived from 24-month-old mice), THEN BRD4 ChIP-seq will reveal stati | Peaks overlapping between all three conditions at minimum 5 of 8 tested NF-κB target loci, with Homer-defined enhancer signatures (H3K27ac+/BRD4+ co-occupancy) | — no observation — | pending | 0.75 |
🔮 Falsifiable Predictions (2)
pendingconf 75%
IF primary murine microglia are primed with three mechanistically distinct stimuli (LPS 100 ng/mL, aggregated Aβ42 2 μM, and serum derived from 24-month-old mice), THEN BRD4 ChIP-seq will reveal statistically significant enhancer overlap (>40% of occupied regions shared across all three conditions)
Predicted outcome: Peaks overlapping between all three conditions at minimum 5 of 8 tested NF-κB target loci, with Homer-defined enhancer signatures (H3K27ac+/BRD4+ co-o
Falsification: BRD4 ChIP-seq reveals stimulus-specific enhancer landscapes with <20% overlap across conditions, or convergent enhancers are absent at key NF-κB target genes (TNF, IL1B, CCL2), indicating distinct rat
pendingconf 68%
IF CRISPR-Cas9 editing deletes a representative convergent BRD4-occupied enhancer (chr11:60.5-60.7 Mb upstream of TREM2) in iPSC-derived microglia-like cells, THEN treatment with JQ1 (300 nM BET inhibitor) will produce >60% reduction in inflammatory cytokine secretion (TNF-α, IL-1β) regardless of wh
Predicted outcome: CRISPR-deleted cells show blunted inflammatory response (TNF release <50 pg/mL) across all challenge conditions compared to wild-type cells, with BET
Falsification: CRISPR deletion of convergent enhancer fails to abrogate hyperinflammatory responses, or BET inhibitor shows stimulus-specific (LPS-responsive only) rather than stimulus-independent suppression of NF-
▸Metadatasource: v1_phase_c_backfill · origin_type: audit_hypothesis_generator
| source | v1_phase_c_backfill |
| origin_type | audit_hypothesis_generator |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.